J. Safra Sarasin Holding AG Takes $699,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

J. Safra Sarasin Holding AG acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 36,453 shares of the company's stock, valued at approximately $699,000.

Several other institutional investors have also recently added to or reduced their stakes in VRDN. R Squared Ltd purchased a new stake in shares of Viridian Therapeutics during the fourth quarter worth about $26,000. AlphaQuest LLC boosted its position in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after acquiring an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after acquiring an additional 1,516 shares during the period. Quantbot Technologies LP acquired a new position in Viridian Therapeutics in the 4th quarter valued at $164,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Viridian Therapeutics during the 4th quarter worth $219,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday. Needham & Company LLC reissued a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $35.70.

Viridian Therapeutics Stock Down 1.6 %

VRDN opened at $13.54 on Thursday. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $27.20. The firm has a 50 day moving average price of $14.34 and a 200 day moving average price of $18.40. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market cap of $1.10 billion, a PE ratio of -3.14 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.24. The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Sell-side analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.